Scarica l'app Stockscreener
201.47
1.42%
2.83
Dopo l'orario di chiusura:
201.45
-0.02
-0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie to Invest $195 Million in US API Manufacturing - PharmTech
AbbVie to invest $195 million in US drug ingredient manufacturing - The American Bazaar
AbbVie (ABBV) Invests US$195 Million To Expand U.S. Pharmaceutical Production - Yahoo Finance
AbbVie to build API plant in Illinois as it steps up US production - BioPharma Dive
Cantor Fitzgerald raises Abbvie stock price target to $215 on strong Skyrizi performance - Investing.com Canada
AbbVie to invest $195M to build plant in Illinois - MSN
AbbVie to invest $195m in new API production facility in US - World Pharmaceutical Frontiers
AbbVie Injects $195 Million Into US Active Pharmaceutical Ingredient Manufacturing - Powder & Bulk Solids
AbbVie investing $195 million in API manufacturing facility - The Pharma Letter
$195M AbbVie Expansion Boosts Illinois Pharma Industry - Business Facilities
AbbVie expands North Chicago API production with $195m investment - Pharmaceutical Technology
AbbVie Invests $195 Million in US API Production - CHEManager
Stock Analysis | Abbvie OutlookBalancing Strong Fundamentals with Mixed Technical and Flow Signals - AInvest
With Thyroid Petition Win, AbbVie Snares Itself; US FDA Sets Up Another Compounding Fight - insights.citeline.com
5 Insightful Analyst Questions From AbbVie’s Q2 Earnings Call - ca.finance.yahoo.com
Illinois secures AbbVie’s $195 million investment for North Chicago facility - MSN
AbbVie To Invest $195 Mln In Illinois API Manufacturing Expansion - Nasdaq
C-Met Mutated Non-Small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Novartis, Apollomics Inc., Abbvie, Janssen Research and Developm - Barchart.com
AbbVie: H1 2025 Earnings Strengthen Case For Targeting Gilgamesh Acquisition (NYSE:ABBV) - Seeking Alpha
AbbVie to invest $195 million in North Chicago facility that will produce active pharmaceutical ingredients - Yahoo Finance
AbbVie details nearly $200M API plant as part of new US investments - Endpoints News
AbbVie to invest $195M in North Chicago manufacturing expansion - The Business Journals
AbbVie to invest $195M to build plant in Illinois (ABBV:NYSE) - Seeking Alpha
AbbVie investing $195 million to expand manufacturing footprint in Illinois - Daily Herald
AbbVie to invest $195 million in expanding Illinois facility - WICS
AbbVie plans $195M expansion of North Chicago plant in U.S. production push - Crain's Chicago Business
AbbVie plans $195M API plant in Illinois as part of US investment campaign - Fierce Pharma
AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S. - Investing News Network
AbbVie announces $195 mln investment to expand active pharmaceutical ingredient manufacturing in U.S. - MarketScreener
AbbVie Invests $195 Million to Construct New Manufacturing Facility in Illinois - MarketScreener
AbbVie's Strategic API Expansion and U.S. Supply Chain Resilience: A New Era for Pharmaceutical Sector Valuation - AInvest
AbbVie to invest $195 million in North Chicago manufacturing expansion By Investing.com - Investing.com Canada
AbbVie invests $195 million in US manufacturing facility expansion - StreetInsider
Short Bowel Syndrome Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Zealand Pharma, Ironwood Pharma, Hanmi Pharma, Shire, AbbVie, Hanmi Pharma - Barchart.com
Piper Sandler starts AbbVie as it sees growth shielded from drug patent losses - Investing.com Canada
If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
Autoinjectors Market Set to Surpass USD 3.02 Billion by 2030 as Demand for Advanced Drug Delivery Systems Accelerates | MarketsandMarkets™. - GlobeNewswire Inc.
AbbVie Gains New Bullish Coverage As Stock Looks To Test $200 - AskTraders.com
Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda - uk.finance.yahoo.com
US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche - GlobeNewswire
AbbVie: Strong Buy Rating Due to Minimal LOE Risks and Growth in Key Segments - TipRanks
Piper Sandler assumes coverage of Abbvie stock with Overweight rating By Investing.com - Investing.com Canada
AbbVie Surges 0.3% on Earnings and Acquisition Hopes as $1.2B Volume Hits Top 500 Rank - AInvest
Alzheimer’s disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therape - Barchart.com
AbbVie’s upadacitinib raises the bar for alopecia areata - Yahoo Finance
4 Overlooked Dividend Aristocrat Stocks with Up To 60%+ Growth Potential - 24/7 Wall St.
AbbVie’s Drug Upadacitinib Shows Positive Phase 3 Results for Severe Alopecia Areata Treatment - Insider Monkey
AbbVie Secures FDA Approval to Expand Mavyret’s Label - MSN
This Insider Has Just Sold Shares In AbbVie - simplywall.st
AbbVie’s Upcoming Study on ABBV-932: What Investors Need to Know - TipRanks
AbbVie's $0.81B Volume Ranks 104th as Stock Falls 0.41% on Mixed Earnings and Analyst Upgrades - AInvest
AbbVie-Genmab cancer collab shows promising results - Crain's Chicago Business
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Genmab/AbbVie’s Epkinly Likely To See Label Expansion After Phase III Win - insights.citeline.com
AbbVie Inc. (ABBV): A Bull Case Theory - MSN
AbbVie Inclusion In Medicare Drug Talks Fails To Justify Lawsuit, Court Rules - Benzinga
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% - Benzinga
AbbVie and Genmab’s Promising B-Cell Lymphoma Trial: A Potential Game-Changer? - The Globe and Mail
AbbVie and Genmab’s Promising Phase 3 Trial for Follicular Lymphoma - The Globe and Mail
AbbVie’s Ubrogepant Study: A Potential Game-Changer for Menstrual Migraine Treatment - The Globe and Mail
AbbVie’s Immunotherapy Trial: A Potential Game-Changer for Advanced Solid Tumors - TipRanks
AbbVie’s Duodopa Study: A Deep Dive into Parkinson’s Treatment - TipRanks
AbbVie Advances Glaucoma Treatment with XEN63 Gel Stent Study - TipRanks
AbbVie’s Promising Phase 3 Study on Upadacitinib for Hidradenitis Suppurativa - TipRanks
AbbVie’s Skyrizi rises to the top for pharma TV ad impressions - Medical Marketing and Media
AbbVie’s upadacitinib holds potential to cement dominant place in alopecia areata - The Pharma Letter
Pfizer and AbbVie Collaborate on Promising Pediatric Antibiotic Study - TipRanks
AbbVie’s Top Executive Makes a Multi-Million Dollar Stock Sale - TipRanks
AbbVie’s Phase 3 Study on Lutikizumab: A Potential Game-Changer for Hidradenitis Suppurativa - TipRanks
AbbVie and Genmab’s Epcoritamab Trial: A Promising Update for B-Cell Lymphoma Treatment - TipRanks
0.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):